Cargando…

Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD

BACKGROUND: Little is known about the link between solar activity and variations in melatonin. In this study, we investigated if melatonin's major urinary metabolite, urinary 6-sulfatoxymelatonin (aMT6s), is lowest under periods of intense solar activity. METHODS: We investigated associations b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zilli Vieira, Carolina L., Koutrakis, Petros, Liu, Man, Gottlieb, Daniel J., Garshick, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037776/
https://www.ncbi.nlm.nih.gov/pubmed/36959654
http://dx.doi.org/10.1186/s12931-023-02390-w
_version_ 1784911947876007936
author Zilli Vieira, Carolina L.
Koutrakis, Petros
Liu, Man
Gottlieb, Daniel J.
Garshick, Eric
author_facet Zilli Vieira, Carolina L.
Koutrakis, Petros
Liu, Man
Gottlieb, Daniel J.
Garshick, Eric
author_sort Zilli Vieira, Carolina L.
collection PubMed
description BACKGROUND: Little is known about the link between solar activity and variations in melatonin. In this study, we investigated if melatonin's major urinary metabolite, urinary 6-sulfatoxymelatonin (aMT6s), is lowest under periods of intense solar activity. METHODS: We investigated associations between high-energy solar particle events [Coronal Mass Ejection (CME) mass, speed and energy] on creatinine-adjusted aMT6s (aMT6sr) concentrations in 140 patients with chronic obstructive pulmonary disease (COPD) using up to four seasonal urine samples (n = 440). Mixed effect models with a random intercept for each subject were used to estimate associations, including effect modification attributable to diabetes, obesity, and reduced pulmonary function. RESULTS: Higher values of CME were associated with reduced aMT6sr concentrations, with stronger associations in patients with diabetes. An interquartile range (IQR) increase in natural log CME(speed) averaged through two days before urine collection was associated with a reduction of 9.3% aMT6sr (95%CI: − 17.1%, − 0.8%) in aMT6sr. There was a greater reduction in aMT6sr in patients with diabetes (− 24.5%; 95%CI: − 35.9%, − 11.6%). In patients without diabetes there was no meaningful association (− 2.2%; 95%CI: − 12%, 8.4%). There were similar associations with CME(energy) and CME(mass). There was no effect modification attributable to reduced pulmonary function or obesity. CONCLUSIONS: This is the first study in patients with COPD to demonstrate strong detrimental impact of high-energy solar particle events on aMT6sr, with greater associations in patients with diabetes. Since melatonin is an anti-oxidant, it is possible that adverse effects of intense solar activity may be attributable to a reduction in circulating melatonin and that patients with both COPD and diabetes may be more susceptible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02390-w.
format Online
Article
Text
id pubmed-10037776
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100377762023-03-25 Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD Zilli Vieira, Carolina L. Koutrakis, Petros Liu, Man Gottlieb, Daniel J. Garshick, Eric Respir Res Research BACKGROUND: Little is known about the link between solar activity and variations in melatonin. In this study, we investigated if melatonin's major urinary metabolite, urinary 6-sulfatoxymelatonin (aMT6s), is lowest under periods of intense solar activity. METHODS: We investigated associations between high-energy solar particle events [Coronal Mass Ejection (CME) mass, speed and energy] on creatinine-adjusted aMT6s (aMT6sr) concentrations in 140 patients with chronic obstructive pulmonary disease (COPD) using up to four seasonal urine samples (n = 440). Mixed effect models with a random intercept for each subject were used to estimate associations, including effect modification attributable to diabetes, obesity, and reduced pulmonary function. RESULTS: Higher values of CME were associated with reduced aMT6sr concentrations, with stronger associations in patients with diabetes. An interquartile range (IQR) increase in natural log CME(speed) averaged through two days before urine collection was associated with a reduction of 9.3% aMT6sr (95%CI: − 17.1%, − 0.8%) in aMT6sr. There was a greater reduction in aMT6sr in patients with diabetes (− 24.5%; 95%CI: − 35.9%, − 11.6%). In patients without diabetes there was no meaningful association (− 2.2%; 95%CI: − 12%, 8.4%). There were similar associations with CME(energy) and CME(mass). There was no effect modification attributable to reduced pulmonary function or obesity. CONCLUSIONS: This is the first study in patients with COPD to demonstrate strong detrimental impact of high-energy solar particle events on aMT6sr, with greater associations in patients with diabetes. Since melatonin is an anti-oxidant, it is possible that adverse effects of intense solar activity may be attributable to a reduction in circulating melatonin and that patients with both COPD and diabetes may be more susceptible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02390-w. BioMed Central 2023-03-24 2023 /pmc/articles/PMC10037776/ /pubmed/36959654 http://dx.doi.org/10.1186/s12931-023-02390-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zilli Vieira, Carolina L.
Koutrakis, Petros
Liu, Man
Gottlieb, Daniel J.
Garshick, Eric
Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD
title Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD
title_full Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD
title_fullStr Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD
title_full_unstemmed Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD
title_short Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD
title_sort intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with copd
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037776/
https://www.ncbi.nlm.nih.gov/pubmed/36959654
http://dx.doi.org/10.1186/s12931-023-02390-w
work_keys_str_mv AT zillivieiracarolinal intensesolaractivityreducesurinary6sulfatoxymelatonininpatientswithcopd
AT koutrakispetros intensesolaractivityreducesurinary6sulfatoxymelatonininpatientswithcopd
AT liuman intensesolaractivityreducesurinary6sulfatoxymelatonininpatientswithcopd
AT gottliebdanielj intensesolaractivityreducesurinary6sulfatoxymelatonininpatientswithcopd
AT garshickeric intensesolaractivityreducesurinary6sulfatoxymelatonininpatientswithcopd